Zhaoke Ophthalmology Gets China Nod for Marketing of Three Eye Drops

MT NewswiresDec 9 19:40

Zhaoke Ophthalmology-B (06622.HK): Latanoprost eye drops, Tafluprost eye drops, and Tafluprost nasal drops have been approved for marketing by the National Medical Products Administration.

On December 9th, Gelonghui reported that Zhaoke Ophthalmology-B (06622.HK) announced that after the Benepali and Bimatoprost eye drops received market approval, the company's glaucoma product portfolio has recently seen three more pharmaceuticals (Latanoprost eye drops, Tafluprost eye drops, and Tafluprost eye drops) approved for sale by the National Medical Products Administration ("NMPA"), which is considered as passing the consistency evaluation for generic drugs. All of the aforementioned pharmaceuticals are produced by the company. These pharmaceuticals, along with Benepali and Bimatoprost eye drops, form a comprehensive glaucoma product portfolio for managing intraocular pressure. The company believes that its production...

Gelonghui FinanceDec 9 17:26

ZHAOKE OPHTH-B (06622.HK) has three glaucoma drugs approved for market release.

ZhaoKe Ophthalmology-B (06622.HK) announced that three more drugs in its glaucoma product portfolio, namely Latanoprost eye drops, Unoprostone eye drops, and Latanoprost tafluprost eye drops, have been approved for marketing by the National Medical Products Administration, which is regarded as passing the consistency evaluation of generic drugs. (vc/u)~

AASTOCKSDec 9 17:23

Good performance, cold stock price, why is Médecins Opticiens "good but not popular" (06622)?

Behind the abnormal stock price performance, is it due to the inadequate market potential of the company's new drugs, the underperformance of the fundamentals, or is there another hidden mystery?

Zhitong FinanceNov 9 16:55

Department of Health: The "1+" approval mechanism will be expanded to all new drugs starting from November, embodying the concept of "Hong Kong, a Good Drug Harbor".

The Department of Health announced today (25th) that, in accordance with the measures announced in the Chief Executive's Policy Address for 2024, the "1+" approval mechanism will be expanded to all new drugs starting from November 1 this year, including vaccines and advanced therapy products, embodying the concept of "good medicine available in Hong Kong." Expanding the "1+" mechanism can attract more new drugs from around the world to register in Hong Kong, providing patients with more choices, strengthening the local drug regulatory capacity, promoting the development of relevant hardware and software, and talent, and further moving towards the "first-level approval." The government will innovate the system in conjunction with technological innovation to develop Hong Kong into an international medical innovation hub. According to the "Pharmacy and Poisons Ordinance".

AASTOCKSOct 25 13:35

Hong Kong stock abnormal | MegaEyes-B (06622) opens more than 9% higher, NVK002 nearsightedness treatment clinical trial shows positive results.

Megain Medical-B (06622) opened more than 9% higher, as of the publication, rose by 9.56%, at 1.49 Hong Kong dollars, with a turnover of 0.2213 million Hong Kong dollars.

Zhitong FinanceOct 24 09:24